Longterm therapy of schizophrenia - Part I: Background, therapeutic aims and pharmacotherapy;Langzeittherapie der schizophrenie - Teil I: Hintergrund, behandlungsziele, pharmakotherapie

Fortschritte der Neurologie Psychiatrie

Volumn 73, Issue 3, 2005, Pages 161-177

  Pajonk, Frank Gerald ^a   Wobrock, T ^a   Falkai, P ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PERPHENAZINE DECANOATE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; ZOTEPINE;

COGNITION; CONTINUING EDUCATION; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SUICIDAL BEHAVIOR;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LONG-TERM CARE; PATIENT COMPLIANCE; PSYCHOTHERAPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ENVIRONMENT; SUICIDE;

EID: 16244412904     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830115     Document Type: Review

References (44)

1. Adams C, Fenton M, Quraishi S, David A. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Second edition. Washington DC: American Psychiatric Association, 2004
3. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2004; CD004028
4. Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Heidelberg, New York: Springer, 2003
5. Carpenter Jr WT, Buchanan RW, Kirkpatrick B, Breier AF. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 1999; 156: 299-303
6. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741-773
7. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde. Praxisleitlinien in Psychiatrie und Psychotherapie. Darmstadt: Steinkopff, 1998
8. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-108
9. Gaebel W, Janner M, Frommann N, Pietzcker A, Kopeke W, Linden M, Muller P, Muller-Spahn F, Tegeler J. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002; 53: 145-159
10. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835-1842
11. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283-1294
12. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
13. Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34-41
14. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003; 64: 34-40
15. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-1132
16. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64: 5-19
17. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003; 64: 1308-1315
18. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998; 172: 413-419
19. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10
20. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
21. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2002; CD001258
22. Lieberman J, Koreen A, Chakos M, Sheitman B, Woerner M, Alvir J, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57: 5-9
23. Maples N, Velligan D, DiCocco M, Castillo D, Lam Y, Ereshefsky L, Korell S, Archuleta D, Miller AL. Has medication adherence improved with the new-generation atypical antipsychotics? Schizophr Res 2003; 60: 325
24. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003; 160: 1405-1412
25. McGorry P, Killackey E, Elkins K, Lambert M, Lambert T. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry 2003; 11: 136-147
26. Mullen J, Jibson M, Sweitzer D. Comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2003; 23: 1839-1854
27. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No. 43. London: National Institute for Clinical Excellence, 2002
28. Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry 2002; 17: 148-154
29. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000; 102: 83-86
30. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64: 1075-1080
31. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128
32. Rijcken CA, Tobi H, Vergouwen AC, de Jong-van den Berg LT. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Saf 2004; 13: 365-370
33. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29: 531-540
34. Schulz SC, Thompson PA, Jacobs M, Ninan PT, Robinson D, Weiden PJ, Yadalam K, Click ID, Odbert CL. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999; 60: 366-372
35. Sernyak MJ, Leslie D, Rosenheck R. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 2003; 160: 310-315
36. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-573
37. Tandon R, Jibson M. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28: 9-26
38. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000; CD000059
39. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300-307
40. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002; CD002305
41. Wobrock T, Falkai P, Pajonk FG. Akuttherapie der Schizophrenie. Fortschr Neurol Psychiatr 2004; 12: 705-726
42. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714-726
43. World Health Organisation (WHO). Schizophrenia: An international Follow-Up-Study. New York: Wiley, 1979
44. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159: 1653-1664